Harsha Reddy, MD
Ophthalmology · New York, NYNPI 1700051919
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,000 of the $6,511 with a category attached, or 61.4%. Amgen accounts for 91.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $6,124 and has fallen 99.4% since, to $39 in 2025.
Across 30 payments — averaging $217.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- Carl Zeiss Meditec Cataract Technology Inc.$192
- GSK$122
- Omeros Corporation$118
- AbbVie$26
- Eyevance Pharmaceuticals LLC$23
- plus $54 from 3 others
What the payments were for
- Speaking & faculty fees$4,00061%
- Travel & lodging$1,63325%
- Food & beverage$85813%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 22 | $5,975 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $192 |
| GSK | 1 | $122 |
| Omeros Corporation | 1 | $118 |
| AbbVie | 1 | $26 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,511 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 121 | $1,104 |
| Prednisolone Acetate | 26 | $686 |
| ErythromycinErythromycin Base | 35 | $337 |
| Ofloxacin | 26 | $195 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.